Fundamental Concepts & Novel Aspects - Screening of Polycystic Ovarian Syndrome (PCOS): In vivo Model

Abstract

Polycystic Ovarian Syndrome (PCOS) is the most common female endocrine disorder, affecting 5-10% of women worldwide. Pathology of PCOS is associated with many abnormal changes such as excessive androgen, insulin resistance, decrease in estrogen and progesterone levels and abnormal gonadotropin level. Currently available therapeutic options include ovulation enhancer, biguanides, glucocorticoids and oral contraceptives. But prognosis with existing therapy is poor because majority of drugs affects only few pathological targets. Moreover, chronic use of these drugs is associated with many adverse effects which limit their usefulness. Use of herbal medicines in such situations can be helpful. Screening models for PCOS: Aromatase inhibitor (Letrozole) induced model. Letrozole concentrations of 1 mg/kg p.o. dissolved in 0.5% or 1.0% CMC (2 mL/kg) once daily; the treatment period is to be 21 days. During this period, vaginal smears will be collected daily and evaluated microscopically with Giemsa staining for estrus cycle determination.